Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting ... (yun Liang Salman M. Hyder Cynthia L. Bes...)

HOME >> MEDICINE >> TECHNOLOGY

Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies

Date:4/14/2008

yun Liang, Salman M. Hyder, Cynthia L. Besch Williford, Indira Benakanakere, Sandra L. Brandt, Philip E. Thorpe. Targeting mutant p53 protein and tumor vasculature: An effective combination therapy for advanced breast tumors, Univ. of Missouri, Columbia, MO, Simmons Cancer Center, University of Texas Southwestern, Dallas, TX, April 14, 2008, 8:00 AM -12:00 PM PDT

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the company will experience delays or difficulties in enrolling patients in the study, the risk that results from future preclinical studies and clinical trials will not correlate with the results of these preclinical studies and the risk that bavituximab will not provide comparable results in combination with other cancer therapies. I
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
3. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
6. Isis Reports Preclinical Data Supporting Liver Safety of ISIS 301012
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
9. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
10. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
11. CorNova Preclinical Results of Valecor Platinum(TM) Coronary Stent Studies Presented at TCT 2007 Conference

Post Your Comments:

(Date:12/15/2009)... -- Medical researchers with EDP Biotech Corporation (EDP) ... technology for a simple blood test to detect ... success of its pre-clinical trials for the ColoMarker(TM) ... biomarker, CA11-19, and all aspects of its use. ... detect colon cancer in its earliest, most curable ...

(Date:12/15/2009)... healthcare providers who have already immunized patients most ... virus may now offer the vaccine to anyone ... today. ,, Pennsylvania is expanding the H1N1 ... doses of vaccine have been allocated to healthcare ... priority groups. ,, "Many certified providers have already ...

(Date:12/15/2009)... YORK, Dec. 15 ,, Reportlinker.com ... is available in its catalogue: ,, ... Market Forecasts to 2015 ,, ... Pipeline Analysis and Market Forecasts to 2015 ... industry analysis specialist,s new report, "Hepatitis B ...

Breaking Medicine Technology:Researchers Announce Medical Breakthrough with Simple, Inexpensive Blood Test for Colon Cancer 2 Department of Health Urges Expanded H1N1 Vaccination Efforts to Include All Patients 2 Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 2 Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 3 Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 4 Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 5 Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 6 Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 7 Prominent Health Experts Who Support Public Insurance Option Available for Interview 51507 1 Prominent Health Experts Who Support Public Insurance Option Available for Interview 51507 2 Prominent Health Experts Who Support Public Insurance Option Available for Interview 51507 3 Prominent Health Experts Who Support Public Insurance Option Available for Interview 51507 4 Prominent Health Experts Who Support Public Insurance Option Available for Interview 51507 5 Americans Wary of Health Legislation 3A University of Texas Zogby Poll to be Released on July 15 National Press Club to Host 22NEWSMAKER 22 Media 51505 1 deCODE Discovers Second Common Genetic Risk Factor for Atrial Fibrillation and Stroke 4719 1 deCODE Discovers Second Common Genetic Risk Factor for Atrial Fibrillation and Stroke 4719 2 deCODE Discovers Second Common Genetic Risk Factor for Atrial Fibrillation and Stroke 4719 3 deCODE Discovers Second Common Genetic Risk Factor for Atrial Fibrillation and Stroke 4719 4

[0] Researchers Announce Medical Breakthrough with Simple, Inexpensive Blood Test for Colon Cancer [0] Department of Health Urges Expanded H1N1 Vaccination Efforts to Include All Patients [0] Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015

... , - Global Clinical ... Asia , Sanofi Pasteur, the ... : SNY), announced today that its investigational tetravalent,dengue vaccine ... to,assess the efficacy of the vaccine in protecting children ...

... with Innovative Manufacturing - Has Potential to Address Gaps ... the 5th World Health Organization Meeting on Evaluation of ... (Nasdaq: NVAX ) announced favorable results from ... trial of its pandemic influenza virus-like particle (VLP) vaccine ...

Other Medicine Technology:Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study 2 Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study 3 Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study 4 Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference 2 Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference 3 Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference 4 Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference 5

Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference

(Date:12/15/2009)... Dec. 15 North American application activity ... November year-over-year, according to the MIB Life ... applications over the past three months have lifted ... of -1.6%, to flat at November,s close, -0.1%. ... interest in the benefits available from life insurance," ...

(Date:12/15/2009)... the United Nations Foundation has led the fight against ... Malaria Report 2009 that the global strategies for ending malaria deaths ... for the United Nations Foundation , ... Washington, D.C. ... United Nations Foundation has led the fight against malaria, and ...

(Date:12/15/2009)... leading provider of secure USB devices, today launches SafeConsole 4.0, ... drive. The software is designed to provide better usability for ... new features and range of licensing options. , ... ... BlockMaster ( www.blockmastersecurity.com ) a leading provider of secure USB ...

(Date:12/15/2009)... -- Reportlinker.com announces that a new ... its catalogue: ,, In-Vitro Diagnostic ... and its International Trade [Q4 2009 ... ,, The newly published In-Vitro Diagnostic ... latest market research on the industry. ...

(Date:12/15/2009)... 15 Reportlinker.com announces that ... available in its catalogue: ,, ... Therapeutics - Market Forecasts to 2015, ... Analysis ,, http://www.reportlinker.com/p0168100/The-Future-of-Autoimmune-Diseases-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html ... The author has released its latest ...

[0] MIB Life Index Reports North American Life Insurance Activity Up 3.9% in November [0] Statement by Dr. Daniel Carucci, Vice President for Global Health for the United Nations Foundation, on Progress Shown in World Malaria Report 2009 [0] BlockMaster Launches SafeConsole 4.0 To Enhance Usability and Security of USB Devices [0] Reportlinker Adds In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition][0] Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

... 2008 - For low-back pain patients and their doctors, ... it is expanding its evidence-based, clinical practice guideline on ... include recommendations on surgery and other interventional treatments. ... at the APS Annual Scientific Meeting. , The ...

... Gloria Estefan at the event to ... benefit St. Jude ... MIAMI, May 9 St. Jude Children,s Research Hospital(R),the world,s premier ... & Stars Gala on Saturday,May 17, at the Adrienne Arsht Center for ...

... U.S. Environmental Protection,Agency has announced that two ... West Michigan in Grand Rapids and the University ... among three programs nationwide,to win EPA,s 2008 National ... programs are providing relief to asthma sufferers in,their ...

... net loss per ... share improves - ... BELLEVILLE, ON, May 9 /PRNewswire-FirstCall/ - Bioniche Life Sciences,Inc. (TSX: BNC), a ... its 2008 fiscal year, ending March 31, 2008., "One highlight of ...

... CareWorks USA and Medical Mutual of,Ohio are ... wellness,programs and absence management solutions to get injured ... the agreement, CareWorks USA will provide workers, compensation,disability, ... management,services. Medical Mutual will provide claims administration and,high-quality ...

... in the,history of Myanmar, the tropical Cyclone Nargis, attacked the ... Friday, May 2, 2008., It is believed that more ... minute by minute. In one small town alone, Bogalay, at ... The,population at risk in the disaster area is about 24 ...

American Pain Society's low back guideline expanded to cover interventional procedures Miami Rolls Out the Red Carpet for Latin Star Studded FedEx/St. Jude Gala Two Michigan Asthma Management Programs Win EPA National Award Bioniche Reports Fiscal 2008 Third Quarter Medical Mutual of Ohio, CareWorks Build a Healthier Workforce Myanmar Cyclone Relief Fund

Girard angled tying forceps made of titanium has angled 45 shafts with 4 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 102 mm....

McPherson curved tying forceps made of titanium has curved shafts with 8 mm tying platforms, width of shafts 0,25 mm, TCI platforms, flat handle, width 6 mm, overall length 85 mm....

Tying forceps with flat serrated handle 88 mm, made of titanium, angled 30 with 4.5 mm tying platform....

Round handle colibri tying forceps with 5 mm titanium coated platforms. Length 100 mm....

Medicine Products:

Girard angled tying forceps Mcpherson curved tying forceps Tying Forceps Colibri tying forceps round handle

Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting ...(yun Liang Salman M. Hyder Cynthia L. Bes...),Health